scholarly journals Neuroprotection by caffeine in the MPTP model of parkinson’s disease and its dependence on adenosine A2A receptors

Neuroscience ◽  
2016 ◽  
Vol 322 ◽  
pp. 129-137 ◽  
Author(s):  
K. Xu ◽  
D.G. Di Luca ◽  
M. Orrú ◽  
Y. Xu ◽  
J.-F. Chen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Adenosine A2a Receptors ◽  
A2a Receptors ◽  
Adenosine A2a ◽  
Mptp Model

Actions of Adenosine A2A Receptors on Synaptic Connections of Spiny Projection Neurons in the Neostriatal Inhibitory Network

2008 ◽  
Vol 99 (4) ◽  
pp. 1884-1889 ◽  
Author(s):  
Tomomi Shindou ◽  
Gordon W. Arbuthnott ◽  
Jeffery R. Wickens
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Synaptic Transmission ◽  
Projection Neurons ◽  
Synaptic Connections ◽  
Adenosine A2a Receptors ◽  
A2a Receptors ◽  
Cells Of Origin ◽  
Adenosine A2a ◽  
Whole Cell Recordings

There is growing evidence that adenosine plays a crucial role in basal ganglia function, particularly in the modulation of voluntary movement. An adenosine-based treatment for Parkinson's disease shows promise in recent clinical studies. Adenosine A2A receptors, the receptors involved in this treatment, are highly expressed in the neostriatum. Previous studies have suggested opposing actions of these receptors on synaptic transmission at striatal and pallidal terminals of the same spiny projection neurons, but the cells of origin of the intrastriatal terminals mediating these actions have not been identified. We used dual whole cell recordings to record simultaneously from pairs of striatal cells; this enabled definitive identification of the presynaptic and postsynaptic cells mediating the effects of A2A receptors. We found that A2A receptors facilitate GABAergic synaptic transmission by intrastriatal collaterals of the spiny projection neurons, consistent with their previously reported actions on synaptic transmission at pallidal terminals. This neuromodulatory action on lateral inhibition in the striatum may underlie, in part, the therapeutic efficacy of adenosine-based treatments for Parkinson's disease.

Gene knockout approach to adenosine A2A receptors in Parkinson's disease

2003 ◽  
Vol 58 (4) ◽  
pp. 354-367 ◽  
Author(s):  
Jiang-Fan Chen ◽  
Michael A. Schwarzschild
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Gene Knockout ◽  
Adenosine A2a Receptors ◽  
A2a Receptors ◽  
Adenosine A2a

scholarly journals Adenosine A2A Receptors Measured with [11C]TMSX PET in the Striata of Parkinson's Disease Patients

PLoS ONE ◽  
2011 ◽  
Vol 6 (2) ◽  
pp. e17338 ◽  
Author(s):  
Masahiro Mishina ◽  
Kiichi Ishiwata ◽  
Mika Naganawa ◽  
Yuichi Kimura ◽  
Shin Kitamura ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Adenosine A2a Receptors ◽  
A2a Receptors ◽  
Adenosine A2a

Targeting adenosine A2A receptors in Parkinson's disease

2006 ◽  
Vol 29 (11) ◽  
pp. 647-654 ◽  
Author(s):  
Michael A. Schwarzschild ◽  
Luigi Agnati ◽  
Kjell Fuxe ◽  
Jiang-Fan Chen ◽  
Micaela Morelli
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Adenosine A2a Receptors ◽  
A2a Receptors ◽  
Adenosine A2a

Quantitation of adenosine A2A receptors availability in Parkinson's Disease patients with and without dyskinesias with [11C]SCH442416 PET using spectral analysis

NeuroImage ◽  
2010 ◽  
Vol 52 ◽  
pp. S216-S217
Author(s):  
Subrata K. Bose ◽  
Anil F. Ramlackhansingh ◽  
Imtiaz Ahmed ◽  
Nicola Pavese ◽  
David J. Brooks ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Spectral Analysis ◽  
Adenosine A2a Receptors ◽  
A2a Receptors ◽  
Adenosine A2a
Sign in / Sign up

Export Citation Format

Share Document